Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($1.05), $0.05 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $25.37 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.